Susquehanna International Group
CGTX icon

Susquehanna International Group’s Cognition Therapeutics CGTX Stock Holding History

Susquehanna International Group’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.3K Buy
80,663
+670
+0.8% +$780 ﹤0.01% 12571
2025
Q4 		$108K Buy
+79,993
New +$130K ﹤0.01% 11412
2024
Q3 		– Sell
-10,182
Closed -$16.9K – 12080
2024
Q2 		$16.9K Buy
+10,182
New +$20.3K ﹤0.01% 11697

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Susquehanna International Group's CGTX Position: Q1 2026 in Review

Susquehanna International Group increased its Cognition Therapeutics (CGTX) stake by 0.84% in Q1 2026, buying an estimated $780 and bringing the position to 80,663 shares worth $61.3K. The position accounts for ﹤0.01% of the portfolio, ranked #12571.

Susquehanna International Group first reported a position in CGTX in Q2 2024 and has held it in 3 quarters since. The position peaked at $108K in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Susquehanna International Group held 80,663 shares of Cognition Therapeutics worth $61.3K as of Q1 2026.
  • Susquehanna International Group bought 670 Cognition Therapeutics shares in Q1 2026, an estimated $780.
  • Cognition Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12571 holding.
  • Susquehanna International Group first reported a position in Cognition Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • Susquehanna International Group's Cognition Therapeutics position peaked at $108K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.